Physician profile
Jeffrey M Wolf
NPI 1164460952
$891,611.85
in general payments reported to CMS, 2019-2025
58 companies · $192K in 2025
The $192K reported for 2025 was more than what 99% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145K · 2020: $38K · 2021: $71K · 2022: $70K · 2023: $178K · 2024: $198K · 2025: $192K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $471K · Travel and Lodging: $56K · Food and Beverage: $28K · Consulting Fee: $12K · Education: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $471,095.70 |
| Travel and Lodging | $56,318.76 |
| Food and Beverage | $28,393.98 |
| Consulting Fee | $11,595.50 |
| Education | $298.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $173,390.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $150,950.58 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $140,059.42 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Regeneron Healthcare Solutions, INC. | $121,276.47 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87,489.54 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $76,466.98 | 2019-2024 | Yupelri, Yupelri |
| Genentech USA, INC. | $62,209.57 | 2019-2023 | Xolair |
| Viatris Specialty LLC | $34,606.95 | 2025 | Yupelri |
| Insmed, INC. | $20,997.64 | 2019-2025 | Arikayce, Brinsupri |
| Advanced Respiratory, INC | $8,029.42 | 2019-2021 | |
| Ethicon INC. | $3,349.18 | 2020-2023 | Monarch Platform |
| Philips North America LLC | $2,173.09 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Sunovion Pharmaceuticals INC. | $1,949.25 | 2019-2021 | |
| Grifols USA, LLC | $1,306.53 | 2019-2025 | Prolastin-C Liquid |
| Novartis Pharmaceuticals Corporation | $947.30 | 2019-2025 |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $759.16 | 2020-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $689.39 | 2019-2024 | Opsumit, Uptravi |
| Electromed, INC. | $636.45 | 2019-2025 | Smartvest |
| Baxter Healthcare | $581.84 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Verona Pharma, INC. | $403.58 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $293.24 | 2019-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Amgen INC. | $263.39 | 2022-2025 | Tezspire |
| Inspire Medical Systems, INC. | $204.16 | 2022-2025 | Inspire |
| Mallinckrodt Enterprises LLC | $201.19 | 2019 | |
| Noah Medical Corporation | $191.68 | 2025 | Galaxy |
| Inogen, INC. | $170.84 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen At Home Stationary Concentrator |
| Vifor Pharma, INC. | $165.52 | 2024-2025 | Zemaira |
| Pfizer INC. | $154.47 | 2019-2024 | |
| Covidien Lp | $154.40 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $144.53 | 2020-2023 | Aralast |
| Medical Device Business Services, INC. | $127.00 | 2022 | |
| Medtronic, INC. | $126.62 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $120.65 | 2019-2023 | |
| Harmony Biosciences LLC | $103.36 | 2022-2023 | Wakix |
| United Therapeutics Corporation | $96.49 | 2023-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $86.71 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $82.81 | 2020-2021 | |
| Intuitive Surgical, INC. | $65.54 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $53.04 | 2023 | Dupixent |
| Jazz Pharmaceuticals INC. | $43.69 | 2019 | |
| Boston Scientific Corporation | $41.70 | 2021-2022 | |
| Shire North American Group INC | $40.16 | 2019 | |
| Genentech, INC. | $39.95 | 2019 | |
| Circassia INC. | $38.09 | 2019 | |
| Gilead Sciences, INC. | $34.34 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $33.95 | 2023 | Nuzyra |
| Chiesi USA, INC. | $33.32 | 2021-2023 | Cleviprex |
| Cumberland Pharmaceuticals, INC. | $31.90 | 2020-2021 | |
| Galvanize Therapeutics, INC | $28.61 | 2023 | Aliya System |
| Optinose US, INC. | $23.13 | 2019 | |
| Merck Sharp & Dohme LLC | $20.90 | 2023 | |
| Resmed Corp | $20.71 | 2023 | |
| Alexion Pharmaceuticals, INC. | $20.38 | 2023 | Ultomiris |
| Phadia US INC. | $20.28 | 2022 | |
| Ani Pharmaceuticals, INC. | $20.04 | 2024 | Purified Cortrophin Gel |
| Shionogi INC | $18.19 | 2024 | Fetroja |
| Veran Medical Technologies, INC. | $14.88 | 2020 | |
| 3b Medical, INC. | $9.12 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.